AB Science SA

AB Science announces dosing of first patient in Phase 2 trial of masitinib’s antiviral activity against the SARS-CoV-2 (COVID-19) virus

29 Nov 2021 11:57:09 By Nasdaq GlobeNewswire

AB Science received FDA authorization to initiate Phase 1/II trial of AB8939 in the treatment of acute myeloid leukemia

22 Nov 2021 09:20:45 By Nasdaq GlobeNewswire

AB Science received authorization from the FDA to resume patient enrollment in the confirmatory Phase 3 study of masitinib (AB19001) in patients with ALS

18 Nov 2021 11:40:53 By Nasdaq GlobeNewswire

AB Science granted authorization from the French Health Authority (ANSM) to initiate a study of AB8939 in the treatment of Acute Myeloid Leukemia (AML)

18 Oct 2021 09:14:05 By Nasdaq GlobeNewswire

AB Science receives FDA authorization to start clinical development program of masitinib in mast cell activation syndrome (MCAS)

04 Oct 2021 09:10:54 By Nasdaq GlobeNewswire

AB Science today reports its revenues for the first half of 2021 and provides an update on its activities

30 Sep 2021 10:21:10 By Nasdaq GlobeNewswire

AB Science receives regulatory authorization to commence a second Phase 2 Covid-19 study

28 Sep 2021 10:25:22 By Nasdaq GlobeNewswire

AB Science receives Health Canada approval letter to commence Phase I/II trial of AB8939 in the treatment of Acute Myeloid Leukemia (AML)

22 Sep 2021 09:09:23 By Nasdaq GlobeNewswire

AB Science announced that an abstract on the long-term survival of masitinib in ALS has been selected for a platform presentation at the Annual Meeting of the Spanish Society of Neurology

20 Sep 2021 10:15:45 By Nasdaq GlobeNewswire

AB Science announced today that it has received authorization to resume patient enrollment in the phase 2 masitinib study of COVID-19 (AB20001)

16 Sep 2021 10:34:08 By Nasdaq GlobeNewswire

AB Science announced that it has received new authorizations to resume patient enrollment in its Phase 3 studies of masitinib

14 Sep 2021 09:01:33 By Nasdaq GlobeNewswire

AB Science announced today that results from masitinib study AB12003 in prostate cancer have been presented at the 2021 American Urological Association

13 Sep 2021 09:04:50 By Nasdaq GlobeNewswire

AB Science announced today that latest clinical data on long-term survival analyses in ALS will be presented at the 2021 symposium on ALS/MND

02 Sep 2021 08:59:01 By Nasdaq GlobeNewswire

AB Science announces that it has received a second authorization to resume patient enrollment, in the Phase 3 study of masitinib in mastocytosis

25 Aug 2021 09:46:55 By Nasdaq GlobeNewswire

AB Science announces that it has received the first authorization to resume patient enrollment in the confirmatory Phase 3 study of masitinib (AB19001) in ALS

23 Aug 2021 10:43:09 By Nasdaq GlobeNewswire

AB Science announced the publication of a pathogenic mechanism triggered by mast cells in the amyotrophic lateral sclerosis (ALS) spinal cord that can be targeted by masitinib

19 Aug 2021 08:51:36 By Nasdaq GlobeNewswire

AB Science publishes a Q&A press release, following-up on its June 28, 2021 press release relating to an agreement with historical shareholders

06 Aug 2021 10:02:25 By Nasdaq GlobeNewswire

AB Science announced that results from its Phase 3 AB09004 study on mild to moderate Alzheimer’s disease have been presented at the AAIC

29 Jul 2021 09:06:56 By Nasdaq GlobeNewswire

AB Science today announced that an abstract reporting results from its Phase 3 AB09004 study on Alzheimer’s disease has been selected for an oral presentation at the annual Alzheimer’s Association International Conference (AAIC)

22 Jul 2021 09:10:35 By Nasdaq GlobeNewswire

AB Science announces the publication of an article in the world-renowned journal Science that confirms potential of masitinib as a treatment of Covid-19 with anti-viral activity against SARS-CoV-2 and all tested variants of concern

20 Jul 2021 09:08:07 By Nasdaq GlobeNewswire